Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies

PURPOSE: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. METHODS: We established 12 PDX from BRAF inhibitor progressed melanoma patients. Following expansion, PDX were analyzed using targeted sequencing...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos, Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordiano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818716/
https://ncbi.nlm.nih.gov/pubmed/26673799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1762
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky